NCT03276429

Brief Summary

In the light of a new era in the management of lung cancer this non-interventional study intend to capture all the epidemiological, clinical, pathological, molecular and treatment parameters of non-small cell (NSCLC) and small cell (SCLC) lung cancer patients from a tertiary Oncology Clinic in an Electronic Data Base (EDB).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
650

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 8, 2017

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

August 23, 2017

Completed
16 days until next milestone

First Posted

Study publicly available on registry

September 8, 2017

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 27, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 27, 2018

Completed
Last Updated

March 14, 2019

Status Verified

March 1, 2019

Enrollment Period

1.4 years

First QC Date

August 23, 2017

Last Update Submit

March 13, 2019

Conditions

Lung Cancer

Keywords

NSCLCSCLCMOLECULAR BIOMARKERS

Outcome Measures

Primary Outcomes (1)

  • Overall survival (OS)

    Overall Survival (OS) will be recorded for all patients and it is defined as the time in months, from diagnosis till death by any cause.

    12months

Secondary Outcomes (2)

  • Response Rate

    12 months

  • Progression Free Survival

    12 months

Study Arms (1)

Lung Cancer patients

All patients with lung cancer that referred to a tertiary Oncology Unit.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients with lung cancer that they have been referred to our Unit will be captured to this electronic database

You may qualify if:

  • \- Since this will be a non-interventional study all adult patients who will be consent for registration of their data to EDB will be enrolled.

You may not qualify if:

  • Patients with insufficient epidemiological or clinical data will be excluded such as patients with no demographic data or patients that have not taken at least 2 cycles of therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

OCEBER

Athens, 11527, Greece

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Konstantinos N Syrigos, MD,PhD

    Non-Governmental, Non-Profit Organization

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 23, 2017

First Posted

September 8, 2017

Study Start

August 8, 2017

Primary Completion

December 27, 2018

Study Completion

December 27, 2018

Last Updated

March 14, 2019

Record last verified: 2019-03

Locations

GR(1)